Zhejiang Shengda Bio-Pharm Co (SHSE:603079) LT-Debt-to-Total-Asset : 0.12 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Shengda Bio-Pharm Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zhejiang Shengda Bio-Pharm Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.12.

Zhejiang Shengda Bio-Pharm Co's long-term debt to total assets ratio increased from Sep. 2023 (0.07) to Sep. 2024 (0.12). It may suggest that Zhejiang Shengda Bio-Pharm Co is progressively becoming more dependent on debt to grow their business.

Zhejiang Shengda Bio-Pharm Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Zhejiang Shengda Bio-Pharm Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Shengda Bio-Pharm Co LT-Debt-to-Total-Asset Chart

Zhejiang Shengda Bio-Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.16

0.08

Zhejiang Shengda Bio-Pharm Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.08	0.10	0.12	0.12

Zhejiang Shengda Bio-Pharm Co LT-Debt-to-Total-Asset Calculation

Zhejiang Shengda Bio-Pharm Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	144	/	1719.186
	=	0.08

Zhejiang Shengda Bio-Pharm Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	211.793	/	1739.661
	=	0.12

Zhejiang Shengda Bio-Pharm Co (SHSE:603079) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zhejiang Shengda Bio-Pharm Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Shengda Bio-Pharm Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Shengda Bio-Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Shengda Bio-Pharm Co Ltd (SHSE:603079) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No.789, Renmin East Road, Chicheng Street, Tiantai County, Zhejiang Province, Hangzhou, CHN, 317200

Website

http://www.sd-pharm.com

Zhejiang Shengda Bio-Pharm Co Ltd is a pharmaceutical company. It is mainly engaged in the research and development, and production of biotin and biological preservatives. Its product portfolio includes biotin, folic acid and other vitamin products, as well as nisin and natamycin.

Executives

Pang Ai Ming	Director
Zhu Yong Gang	Director

Zhejiang Shengda Bio-Pharm Co Headlines

No Headlines